Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance

ResMed Inc.Trade
Direxion Daily 20 Year Treasury Bull 3X SharesTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.42. The key difference: ResMed Inc. pays a 1.19% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and ResMed Inc. is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.

RMDTMF
Market Cap
$31.89B
Sector
HealthLeveraged / Inverse
52-Week High
$283.28$44.14
52-Week Low
$182.82$29.83
Enterprise Value
$31.24B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

Direxion Daily 20 Year Treasury Bull 3X Shares

TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $30.85, down 0.13% for the day, with a bearish technical signal driven by moving averages. The stock faces significant long-term erosion, as highlighted by a recent article showing a $10,000 investment five years ago would now be worth about $1,527. Key support lies at $30, with resistance at $31.

The outlook remains challenged by interest rate sensitivity and leverage decay, posing risks for investors seeking Treasury exposure. Opportunities may arise from potential Federal Reserve policy shifts, but volatility and structural ETF risks demand caution.

Returns comparison

Trailing returns across standard periods

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About Direxion Daily 20 Year Treasury Bull 3X Shares

TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.

Read more on TMF